Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose
vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily
practice